A5057743401- Cancer Treatment and Pharmacology
- Neutropenia and Cancer Infections
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Hepatocellular Carcinoma Treatment and Prognosis
- Lung Cancer Treatments and Mutations
- Advanced Breast Cancer Therapies
- Biosimilars and Bioanalytical Methods
- Gastric Cancer Management and Outcomes
- Blood disorders and treatments
- Fungal Infections and Studies
- Breast Cancer Treatment Studies
- Monoclonal and Polyclonal Antibodies Research
- Cancer Genomics and Diagnostics
- Molecular Biology Techniques and Applications
- Gene expression and cancer classification
- Health Systems, Economic Evaluations, Quality of Life
- Nausea and vomiting management
- Radiopharmaceutical Chemistry and Applications
- Head and Neck Cancer Studies
- Cancer Diagnosis and Treatment
- Colorectal and Anal Carcinomas
- Estrogen and related hormone effects
- Venous Thromboembolism Diagnosis and Management
- Multiple and Secondary Primary Cancers
Samara Medical Institute Reaviz
2018-2024
Samara Regional Clinical Oncology Center
2011-2016
PURPOSE To compare giredestrant and physician's choice of endocrine monotherapy (PCET) for estrogen receptor–positive, HER2-negative, advanced breast cancer (BC) in the phase II acelERA BC study (ClinicalTrials.gov identifier: NCT04576455 ). METHODS Post-/pre-/perimenopausal women, or men, age 18 years older with measurable disease/evaluable bone lesions, whose disease progressed after 1-2 lines systemic therapy (≤1 targeted, ≤1 chemotherapy regimen, prior fulvestrant allowed) were randomly...
Cetuximab in combination with an irinotecan-containing regimen is a standard treatment patients KRAS wild-type (KRAS WT), metastatic colorectal cancer (mCRC). We investigated the addition of oral MET inhibitor tivantinib to cetuximab + irinotecan (CETIRI) based on preclinical evidence that activation pathway may confer resistance anti-EGFR therapy. Previously treated WT advanced or mCRC were enrolled. The phase 1, open-label 3 3, dose-escalation study evaluated safety and maximally tolerated...
This study evaluated the safety and efficacy of recombinant human intestinal trefoil factor (rhITF) administered as topical oral spray for prevention treatment chemotherapy-induced mucositis (OM).Ninety-nine patients with colorectal cancer who had moderate to severe OM (WHO grade >or= 2) in first cycle chemotherapy were randomly assigned receive either placebo, rhITF 10 mg/mL (ie, low dose), or 80 high dose) by (300 microL, eight times each day) 14 consecutive days second cycle. Patients...
3508 Background: Tivantinib (ARQ 197) selectively inhibits the MET receptor tyrosine kinase, which is implicated in tumor cell migration, invasion, and metastasis. Resistance to EGFR inhibitors has been associated with activation of alternative pathways including MET. Methods: Pts advanced KRAS WT CRC that progressed on or after 1 prior line chemotherapy no previous treatment an inhibitor were eligible. randomized 1:1 receive cetuximab (500 mg/m 2 ) irinotecan (180 days 15 every 28 days,...
8057 Background: BCD-021 demonstrated equivalence to Avastin in a comprehensive comparability exercise that included physicochemical, PK and PD studies, as well phase I clinical study patients with non-squamous NSCLC. Methods: 138 advanced NSCLC (stage IIIb/IV) were randomly assigned into 2 groups at ratio of 1:1 receive or dose 15 mg/kg combination paclitaxel (175 mg/m2) carboplatin (AUC 6 mg/ml×min) every 3 weeks up cycles therapy until progression unbearable toxicity. Results: ORR...
3582 Background: ARQ 197 selectively inhibits the c-MET receptor tyrosine kinase (RTK) which has been implicated in tumor cell migration, invasion, proliferation, and angiogenesis. CPT-11 plus C is a standard of care for CPT-11-refractory mCRC pts with WT KRAS tumors. Resistance to associated activation alternative RTK pathways including c-MET. We hypothesize that adding may decrease resistance therapy improve pt outcomes. Methods: The primary objectives phase I study were evaluate safety...
e13500 Background: BCD-021 is a bevacizumab biosimilar candidate manufactured by CJSC BIOCAD, Russia. Full spectrum of physicochemical and preclinical studies showed equivalence to innovator drug Avastin. Methods: 28 patients with advanced non-squamous NSCLC (stage IIIb/IV) were enrolled in the study. Patients randomly assigned into 2 groups at ratio 1:1 receive or Avastin dose 15 mg/kg combination paclitaxel (175 mg/m2) carboplatin (AUC 6 mg/ml×min) every 3 weeks. The primary endpoint was...
e11576 Background: BCD-022 is a trastuzumab biosimilar candidate manufactured by CJSC BIOCAD, Russia. Full spectrum of physicochemical and preclinical studies showed equivalence to innovator drug trastuzumab. Methods: 46 patients with HER2(+) mBC were enrolled in the study. Patients randomly assigned into 2 groups at ratio 1:1 receive or (a single loading dose 8 mg/kg maintenance 6 mg/kg) paclitaxel (175 mg/m2) every 3 weeks. The primary endpoint was AUC(0-504), secondary endpoints included...
Treatment of cancer often requires the use adjuvant chemotherapy (ACT). In real clinical practice, numerous patients suffer from severe toxicity and reduced quality life (QoL). Hence, there is a need to maintain QoL reduce therapy comply with recommended (CT) regimens. The present study focused on effects multi-component nutritional supplement Oncoxin (ONCX) CT-induced in undergoing ACT. A total 133 aged 50-70 years gastric IIB-IIIC or non-small cell lung IIB-IIIA were enrolled study: 84...
e20735 Background: Empegfilgrastim is an innovator drug product of pegylated G-CSF indicated for prophylaxis neutropenia in patients receiving myelosuppressive chemotherapy. Methods: Objective was to compare safety and efficacy a single dose empegfilgrastim daily dosing filgrastim docetaxel 75 mg/m2 + doxorubicin 50 mg/m2. 135 with breast cancer were randomly assigned at ratio 1:1:1 receive either s.c. injection doses 6 mg or 7.5 mg, injections 5 mcg/kg (until ANC ≥ 10x109/L). Results: At...
Background. Breast cancer is one of the most common female malignancies. Molecular diagnostic methods tumor profiling allow us to analyze individual characteristics, identify new prognostic and predictive markers. Aim. To increase efficacy systemic therapy for breast reduce inappropriate prescriptions using data on molecular characteristics; develop a polygenic panel ensure tailored approach cancer. Materials methods. We analyzed 84 tissue samples from pre- postmenopausal women with...
In patients with malignant neoplasms, the incidence of symptomatic venous thromboembolism (VTE) is 4–7 times higher than in general population. The presence distant metastases solid tumors increases risk VTE. Most often, VTE develops pancreatic and stomach cancers. Chemotherapy development. Low-molecular-weight heparin direct oral anticoagulants are used for treatment receiving chemotherapy. Prior to start chemotherapy, it necessary assess development using Khorana score. Outpatient...
Squamous cell carcinoma of the head and neck (SCCHN) is one causes cancer mortality. The mortality rate patients within a year from moment diagnosis reaches 27% in with tumors oral cavity 35.2% pharynx. Despite visual localization SCCHN more than 50% at time are not subject to radical surgical treatment. More half develop relapses 3 years after end Most receive antitumor drug therapy either when an unresectable/metastatic tumor detected or relapse develops previously performed Epidermal...
.
РЕЗУЛЬТАТЫ МНОГОЦЕНТРОВОГО ДВОЙНОГО СЛЕПОГО РАНДОМИЗИРОВАННОГО КЛИНИЧЕСКОГО ИССЛЕДОВАНИЯ ПЕРВОЙ ФАЗЫ ПРЕПАРАТА BCD-022 ПО СРАВНЕНИЮ С ПРЕПАРАТОМ ГЕРЦЕПТИН®, ПРИМЕНЯЕМЫХ В СОЧЕТАНИИ ПАКЛИТАКСЕЛОМ У БОЛЬНЫХ МЕТАСТАТИЧЕСКИМ РАКОМ МОЛОЧНОЙ ЖЕЛЕЗЫ
Bewertung der Lokalrezidivrate und des kosmetischen Ergebnisses nach Applikation eines intraoperativen Elektronen-Boostes kombiniert mit postoperativer hypofraktionierter Ganzbrustbestrahlung.
e12012 Background: One of the most serious potential side effects chemotherapy is neutropenia. Grade 3 and 4 neutropenia especially problematic because increased incidence infections, hospitalization, antibiotic treatment, necessity to reduce therapy intensity. The intensity adjuvant key successful treatment. Dicarbamin agent for prevention chemotherapy-induced decreases dystrophic changes in myeloid progenitor cells relative number with signs apoptosis. We conducted an analysis efficacy...
Background. Individual molecular characteristics of a tumor can serve as basis for tailored approach to therapy, prediction the disease course and outcome, timely treatment correction in cancer patients. Tumor genomic profiling allows more precise assessment an individual manner. Accurate identification HER2 status breast is crucial clinical decisions appropriate strategy. Aim. To increase efficacy systemic therapy cancer, reduce inappropriate prescribing, ensure using information on tumor....